U.S. Stock Futures Edge Up as Markets Eye Fed Signals and Q3 Earnings 
Major Gaps in Home Loan Data Raise Concerns Over Discriminatory Lending and Accountability 
Saudi Arabia Raises Oil Prices for Asia Amid Market Volatility and Middle East Tensions 
U.S. Inflation, Fed Meeting, Earnings Season, and Oil Prices: A Market Outlook for the Week 
JPMorgan Analysts Forecast Bitcoin and Gold Surge Amid Geopolitical Tensions and U.S. Election 
Higher-than-Expected September Inflation Delays Turkey’s Anticipated Interest Rate Cuts 
U.S. Services Sector Hits 1.5-Year High in September as Employment Weakens 
Oil Prices Dip Amid Middle East Tensions & Positive U.S. Data 
Wall Street Reconsiders Fed’s Half-Point Rate Cut as Inflation Concerns Resurface 
U.S. Retailers Adapt to East Coast and Gulf Coast Port Strikes: Strategies for Ensuring Holiday Supply Chain Stability 
Canvas: A New Collaborative Interface for ChatGPT Users 
Asian Markets Rally Amid Strong U.S. Labor Data 
China’s Foreign Exchange Reserves Beat Forecasts with $28.2 Billion Rise in September 
U.S. Dock Workers Strike Ends with Tentative Wage Deal, Avoiding Major Supply Chain Disruptions 
S&P 500 News: Markets Fall Amid Labor Data and Middle East Tensions 
Activist investor Starboard Value has acquired a $1 billion stake in Pfizer to push for strategic changes in the U.S. pharmaceutical giant. This investment comes as Pfizer contends with declining sales of its COVID-19 vaccines and treatments, underwhelming sales for its RSV vaccine, and failed clinical trials for an obesity medication.
Former Pfizer Executives to Aid Starboard’s Efforts
Starboard has approached Ian Read, Pfizer’s CEO until 2019, and Frank D’Amelio, who served as CFO until 2021. Both former executives are interested in helping Starboard steer the company toward renewed growth.
Stock Price Decline Post-COVID Success
Albert Bourla, who became CEO in 2019, was key in partnering with BioNTech to develop Pfizer's COVID-19 vaccine. However, as pandemic demand wanes, the company’s stock has plummeted from approximately $41 to $28.58 as of last Friday, reflecting concerns over weakened vaccine demand and disappointing new product launches.
Aggressive Acquisitions Draw Scrutiny
Since 2020, Pfizer has made over $70 billion in acquisitions, including major deals like Seagen for $43 billion, Biohaven for $13 billion, Arena for $6 billion, Global Blood Therapeutics for $5 billion, and Trillium for $2 billion. The acquisitions have raised investor concerns, especially regarding GBT’s sickle cell drug, which faced market withdrawal due to severe side effects and discontinuation of related studies.
Starboard’s History of Corporate Overhauls
Known for pushing changes in major companies like News Corp, Salesforce, and Match Group, Starboard Value's influence could lead to significant shifts in Pfizer's strategic direction.
The Wall Street Journal first reported Starboard’s Pfizer stake. Neither Pfizer nor Starboard has officially commented on the investment or potential next steps.
